<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02594059</url>
  </required_header>
  <id_info>
    <org_study_id>2012/56</org_study_id>
    <nct_id>NCT02594059</nct_id>
  </id_info>
  <brief_title>Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis</brief_title>
  <acronym>Endoth-FPI</acronym>
  <official_title>Assessment of Peripheral Endothelial Function in Idiopathic Pulmonary Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hopital Foch</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hopital Foch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the peripheral endothelial function in adult patients with&#xD;
      idiopathic pulmonary fibrosis (IPF) and the relationship between the peripheral endothelial&#xD;
      function and the severity of the IPF.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary criteria is the peripheral endothelial function that will be assessed by the&#xD;
      measure of flow-mediated dilation (reactive hyperemia-peripheral artery tone index). The&#xD;
      pulmonary function will be assessed by the measures of the forced expiratory volume at one&#xD;
      second (FEV1), the forced vital capacity (FVC) and the total lung capacity (TLC) and the&#xD;
      diffusing capacity of the lung for carbon monoxide (DLCO). The dyspnea will be assessed with&#xD;
      the New York Heart Association (NYHA) score. The exercise capacity will be assessed by the&#xD;
      6-min walk test. Pulmonary arterial pressure will be recorded through cardiac echography or&#xD;
      catheterization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 19, 2012</start_date>
  <completion_date type="Actual">July 15, 2020</completion_date>
  <primary_completion_date type="Actual">July 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>measure of reactive hyperemia-peripheral artery tone index</measure>
    <time_frame>day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>endothelial function</measure>
    <time_frame>1, 2 and 3 years</time_frame>
    <description>measure of reactive hyperemia-peripheral artery tone index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>measure of reactive hyperemia-peripheral artery tone index</measure>
    <time_frame>3 years</time_frame>
    <description>measure of reactive hyperemia-peripheral artery tone index at IPF exacerbation or PAHT's occurence</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">43</enrollment>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>Pulmonary idiopathic fibrosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with pulmonary idiopathic fibrosis according to ATS/ERS 2011's criteria</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>endothelial function</intervention_name>
    <description>measure of reactive hyperemia-peripheral artery tone index</description>
    <arm_group_label>Pulmonary idiopathic fibrosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  IPF according to ATS/ERS 2011's criteria&#xD;
&#xD;
          -  Stable IPF (no reduction of FVC or DLCO of more than 10% and 15% respectively)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a significant disease other than IPF. A significant disease is defined&#xD;
             as a disease which, in the opinion of the investigator, may influence the results of&#xD;
             the trial.&#xD;
&#xD;
          -  Pregnant or nursing women.&#xD;
&#xD;
          -  Non-pulmonary fibrosis&#xD;
&#xD;
          -  treatment by pulmonary vasodilators that cannot be stopped for 24 hours for the&#xD;
             assessment of endothelial function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hopital Europeen Georges Pompidou, dpt of pneumology</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 29, 2015</study_first_submitted>
  <study_first_submitted_qc>October 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2015</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>endothelial function, idiopathic pulmonary fibrosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

